D. Western Therapeutics Institute, Inc. (4576.T)
JPY 112.0
(1.82%)
JPY 112.0
(1.82%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -982.14 Million JPY | 28.15% |
| 2022 | -1.36 Billion JPY | 14.23% |
| 2021 | -1.59 Billion JPY | 13.77% |
| 2020 | -1.84 Billion JPY | -74.23% |
| 2019 | -1.06 Billion JPY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -192.05 Million JPY | 51.19% |
| 2024 Q1 | -393.45 Million JPY | 59.94% |
| 2023 Q4 | -982.14 Million JPY | 18.96% |
| 2023 FY | -982.14 Million JPY | 28.15% |
| 2023 Q3 | -1.21 Billion JPY | 13.84% |
| 2023 Q2 | -1.4 Billion JPY | 0.45% |
| 2023 Q1 | -1.41 Billion JPY | -3.37% |
| 2022 Q4 | -1.36 Billion JPY | -8.73% |
| 2022 Q3 | -1.25 Billion JPY | 0.0% |
| 2022 FY | -1.36 Billion JPY | 14.23% |
| 2021 FY | -1.59 Billion JPY | 13.77% |
| 2020 FY | -1.84 Billion JPY | -74.23% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 742.75 Million JPY | 232.229% |
| PRISM BioLab Co.,LTD | -1.13 Billion JPY | 13.387% |
| GNI Group Ltd. | -17.93 Billion JPY | 94.523% |
| Linical Co., Ltd. | -4.46 Billion JPY | 77.995% |
| Trans Genic Inc. | -221.16 Million JPY | -344.069% |
| MEDINET Co., Ltd. | -4.39 Billion JPY | 77.648% |
| Soiken Holdings Inc. | -4.79 Billion JPY | 79.496% |
| Cytori Cell Research Institute, Inc. | 1.43 Billion JPY | 168.512% |
| AnGes, Inc. | -3.79 Billion JPY | 74.139% |
| OncoTherapy Science, Inc. | -420.8 Million JPY | -133.395% |
| Nxera Pharma Co., Ltd. | 24.9 Billion JPY | 103.943% |
| Immuno-Biological Laboratories Co., Ltd. | -498.15 Million JPY | -97.156% |
| NanoCarrier Co., Ltd. | -466.34 Million JPY | -110.603% |
| Carna Biosciences, Inc. | -2.7 Billion JPY | 63.707% |
| CanBas Co., Ltd. | -1.88 Billion JPY | 47.985% |
| RaQualia Pharma Inc. | -3.39 Billion JPY | 71.088% |
| Chiome Bioscience Inc. | -1.03 Billion JPY | 5.066% |
| Kidswell Bio Corporation | 343.58 Million JPY | 385.848% |
| PeptiDream Inc. | 3.29 Billion JPY | 129.834% |
| Oncolys BioPharma Inc. | -972.59 Million JPY | -0.982% |
| Ribomic Inc. | -2.09 Billion JPY | 53.226% |
| SanBio Company Limited | -3.78 Billion JPY | 74.084% |
| Healios K.K. | -2.19 Billion JPY | 55.153% |
| BrightPath Biotherapeutics Co., Ltd. | -944.85 Million JPY | -3.946% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -2.62 Billion JPY | 62.573% |
| Delta-Fly Pharma, Inc. | -1.41 Billion JPY | 30.692% |
| StemRIM | -8.41 Billion JPY | 88.322% |
| CellSource Co., Ltd. | -4.68 Billion JPY | 79.03% |
| FunPep Company Limited | -1.79 Billion JPY | 45.235% |
| Kringle Pharma, Inc. | -2.13 Billion JPY | 54.03% |
| Stella Pharma Corporation | -1.11 Billion JPY | 12.262% |
| TMS Co., Ltd. | -3.44 Billion JPY | 71.504% |
| Noile-Immune Biotech Inc. | -5.55 Billion JPY | 82.322% |
| Cuorips Inc. | -5.56 Billion JPY | 82.339% |
| K Pharma,Inc. | -3.26 Billion JPY | 69.932% |
| Takara Bio Inc. | -32.2 Billion JPY | 96.95% |
| ReproCELL Incorporated | -2.93 Billion JPY | 66.583% |
| PhoenixBio Co., Ltd. | -660.96 Million JPY | -48.593% |
| StemCell Institute Inc. | -2.83 Billion JPY | 65.378% |
| Japan Tissue Engineering Co., Ltd. | -2.06 Billion JPY | 52.47% |
| CellSeed Inc. | -2.01 Billion JPY | 51.187% |